Cargando…

Design of therapeutic vaccines: hepatitis B as an example

Therapeutic vaccines are currently developed for chronic viral infections, such as human papillomavirus (HPV), human immunodeficiency virus (HIV), herpesvirus and hepatitis B (HBV) and C (HCV) virus infections. As an alternative to antiviral treatment or to support only partially effective therapy a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kutscher, Sarah, Bauer, Tanja, Dembek, Claudia, Sprinzl, Martin, Protzer, Ulrike
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2012
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3815787/ https://www.ncbi.nlm.nih.gov/pubmed/21958338 http://dx.doi.org/10.1111/j.1751-7915.2011.00303.x

Ejemplares similares

Increased HERV-K(HML-2) Transcript Levels Correlate with Clinical Parameters of Liver Damage in Hepatitis C Patients
por: Weber, Melanie, et al.
Publicado: (2021)

Overnight Resting of PBMC Changes Functional Signatures of Antigen Specific T- Cell Responses: Impact for Immune Monitoring within Clinical Trials
por: Kutscher, Sarah, et al.
Publicado: (2013)

Improving Therapeutic Vaccination against Hepatitis B—Insights from Preclinical Models of Immune Therapy against Persistent Hepatitis B Virus Infection
por: Knolle, Percy A., et al.
Publicado: (2021)

PD-L1 Silencing in Liver Using siRNAs Enhances Efficacy of Therapeutic Vaccination for Chronic Hepatitis B
por: Bunse, Till, et al.
Publicado: (2022)

Immunogenicity and Antiviral Response of Therapeutic Hepatitis B Vaccination in a Mouse Model of HBeAg-Negative, Persistent HBV Infection
por: Kosinska, Anna D., et al.
Publicado: (2021)

Control of Hepatitis B Virus by Cytokines
por: Xia, Yuchen, et al.
Publicado: (2017)

Hepatitis B Vaccine Non-Responders Show Higher Frequencies of CD24(high)CD38(high) Regulatory B Cells and Lower Levels of IL-10 Expression Compared to Responders
por: Körber, Nina, et al.
Publicado: (2021)

Can Engineered “Designer” T Cells Outsmart Chronic Hepatitis B?
por: Protzer, U., et al.
Publicado: (2010)

Evaluation of the Effect of CD70 Co-Expression on CD8 T Cell Response in Protein-Prime MVA-Boost Vaccination in Mice
por: Stephan, Ann-Sophie, et al.
Publicado: (2023)

Isolation and functional characterization of hepatitis B virus-specific T-cell receptors as new tools for experimental and clinical use
por: Wisskirchen, Karin, et al.
Publicado: (2017)

Efficient stabilization of therapeutic hepatitis B vaccine components by amino-acid formulation maintains its potential to break immune tolerance
por: Sacherl, Julia, et al.
Publicado: (2022)

Synergy of therapeutic heterologous prime-boost hepatitis B vaccination with CpG-application to improve immune control of persistent HBV infection
por: Kosinska, Anna D., et al.
Publicado: (2019)

P18-04. MVA-nef vaccination induces specific T-cell responses exerting functions associated with non-progressive disease in HIV-1 infected individuals
por: Kutscher, S, et al.
Publicado: (2009)

Hepatitis B Virus Activates Signal Transducer and Activator of Transcription 3 Supporting Hepatocyte Survival and Virus Replication
por: Hösel, Marianna, et al.
Publicado: (2017)

Global Occurrence of Clinically Relevant Hepatitis B Virus Variants as Found by Analysis of Publicly Available Sequencing Data
por: Velkov, Stoyan, et al.
Publicado: (2020)

Designing a therapeutic hepatitis B vaccine to circumvent immune tolerance
por: Whitacre, DC, et al.
Publicado: (2019)

Evaluation of T-activated proteins as recall antigens to monitor Epstein–Barr virus and human cytomegalovirus-specific T cells in a clinical trial setting
por: Körber, Nina, et al.
Publicado: (2020)

Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial
por: Zoulim, Fabien, et al.
Publicado: (2019)

The Global Hepatitis B Virus Genotype Distribution Approximated from Available Genotyping Data
por: Velkov, Stoyan, et al.
Publicado: (2018)

Secreted Interferon-Inducible Factors Restrict Hepatitis B and C Virus Entry In Vitro
por: Xia, Yuchen, et al.
Publicado: (2017)

Applicability of Metal Nanoparticles in the Detection and Monitoring of Hepatitis B Virus Infection
por: Shevtsov, Maxim, et al.
Publicado: (2017)

Validation of an IFNγ/IL2 FluoroSpot assay for clinical trial monitoring
por: Körber, Nina, et al.
Publicado: (2016)

Viral hepatitis and liver cancer
por: Ringehan, Marc, et al.
Publicado: (2017)

Hepatitis B Virus Impairs TLR9 Expression and Function in Plasmacytoid Dendritic Cells
por: Vincent, Isabelle E., et al.
Publicado: (2011)

Depletion of T cells via Inducible Caspase 9 Increases Safety of Adoptive T-Cell Therapy Against Chronic Hepatitis B
por: Klopp, Alexandre, et al.
Publicado: (2021)

Correction to ‘Viral hepatitis and liver cancer’
por: Ringelhan, Marc, et al.
Publicado: (2018)

Innate immune recognition and modulation in hepatitis D virus infection
por: Jung, Stephanie, et al.
Publicado: (2020)

How Do Experts and Nonexperts Want to Promote Vaccines? Hepatitis E Vaccine as Example
por: Ren, Hong, et al.
Publicado: (2019)

Rapid and Robust Continuous Purification of High-Titer Hepatitis B Virus for In Vitro and In Vivo Applications
por: Wettengel, Jochen M., et al.
Publicado: (2021)

Using a Mixed IRT Model to Assess the Scale Usage in the Measurement of Job Satisfaction
por: Kutscher, Tanja, et al.
Publicado: (2017)

Sample Size Requirements for Applying Mixed Polytomous Item Response Models: Results of a Monte Carlo Simulation Study
por: Kutscher, Tanja, et al.
Publicado: (2019)

Cost evaluation of PAGE-B risk score guided HCC surveillance in patients with treated chronic hepatitis B
por: Sprinzl, Martin F., et al.
Publicado: (2021)

On the future of therapeutic vaccination in chronic hepatitis B
por: Aguilar Rubido, Julio Cesar
Publicado: (2019)

Therapeutic vaccination for treatment of chronic hepatitis B
por: Cargill, Tamsin, et al.
Publicado: (2021)

Nef-specific CD45RA+ CD8+ T cells secreting MIP-1β but not IFN-γ are associated with nonprogressive HIV-1 infection
por: Dembek, Claudia J, et al.
Publicado: (2010)

Mechanistic principles of an ultra-long bovine CDR reveal strategies for antibody design
por: Svilenov, Hristo L., et al.
Publicado: (2021)

Mitosis of hepatitis B virus-infected cells in vitro results in uninfected daughter cells
por: Tu, Thomas, et al.
Publicado: (2022)

N-Glycosylation of the Na+-Taurocholate Cotransporting Polypeptide (NTCP) Determines Its Trafficking and Stability and Is Required for Hepatitis B Virus Infection
por: Appelman, Monique D., et al.
Publicado: (2017)

Plasma lactate measurement as an example of encountered gaps between routine clinical laboratory processes and manufactures' sample-handling instructions
por: Hashim, Ibrahim A., et al.
Publicado: (2018)

Concentration of Na(+)-taurocholate-cotransporting polypeptide expressed after in vitro-transcribed mRNA transfection determines susceptibility of hepatoma cells for hepatitis B virus
por: Oswald, Andreas, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_u0elkfqnt7jmvlknocebl66at0